Search results for: '2017 dure alliances review'
- Did you mean
- 2016 drug alliances review
- Related search terms
- dure+chapter+scienc+2025
- dure+chapter+sciences+2025
- dure cultur scienc 2025
- dure+captura+scienc+2025
- dure chapter sciences 2025
-
Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019 to 2026March 2026$3,995.00Asset Purchase Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2026
Learn More -
Discovery Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026March 2026$4,995.00The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers in-depth insights and exclusive access to discovery-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.
Learn More -
Central Nervous System (CNS) Collaboration and Licensing Deals 2020-2025October 2015$3,995.00Central Nervous System (CNS) Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2020 to 2025
Learn More -
Genomic Collaboration and Licensing Deals 2018-2025November 2025$3,995.00Genomics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2018 to 2025
Learn More -
Generic Pharmaceutical Partnering Terms and Agreements 2010-2026January 2026$3,995.00Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals.
Learn More -
Royalty Rates in Pharmaceutical and Biotechnology Deals 2015 to 2026March 2026$4,995.00Essential Benchmark Data for Dealmakers | Global coverage | Updated to 2026 | 11+ years of royalty rates | Deal financials | Contract documents | Royalty rate trends
Learn More -
Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025November 2025$3,995.00Cancer Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025
Learn More -
Monoclonal Antibody Collaboration and Licensing Deals 2019-2025November 2025$3,995.00Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025
Learn More -
Viral Vector Collaboration and Licensing Deals 2016-2025November 2025$3,995.00Viral Vector Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025
Learn More -
Vaccine Collaboration and Licensing Deals 2016-2025November 2025$3,995.00Vaccine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025
Learn More
